Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline

MLA

Raj Rajagovindan, et al. “Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing in Clinical Decline.” Alzheimer’s & Dementia, vol. 17, Dec. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........84ceb6ec4b7e30922891dc62fdc4455b&authtype=sso&custid=ns315887.

APA

Raj Rajagovindan, Tianle Chen, Laura Nisenbaum, Ying Tian, Kumar Kandadi Muralidharan, Gersham Dent, Ping He, Carmen Castrillo‐Viguera, & Samantha Budd Haeberlein. (2021). Reductions in biomarkers of Alzheimer’s disease pathophysiology following treatment with aducanumab were associated with slowing in clinical decline. Alzheimer’s & Dementia, 17.

Chicago

Raj Rajagovindan, Tianle Chen, Laura Nisenbaum, Ying Tian, Kumar Kandadi Muralidharan, Gersham Dent, Ping He, Carmen Castrillo‐Viguera, and Samantha Budd Haeberlein. 2021. “Reductions in Biomarkers of Alzheimer’s Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing in Clinical Decline.” Alzheimer’s & Dementia 17 (December). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........84ceb6ec4b7e30922891dc62fdc4455b&authtype=sso&custid=ns315887.